Ewha Med J.  2023 Dec;46(S1):e31. 10.12771/emj.2023.e31.

Updates in the Management of Graves Disease in Children

• Lee YJ

• KMID: 2550851
• DOI: http://doi.org/10.12771/emj.2023.e31

Abstract

Graves disease (GD) is the primary cause of hyperthyroidism in children. The standard management options—namely, antithyroid drugs (ATD), radioactive iodine, and surgery—have not changed for many years. Although ATD therapy is often the first-line treatment for pediatric patients, the low likelihood of spontaneous remission means that most children will require a more permanent solution. Recent clinical trials and systematic reviews have shed light on the long-term outcomes of ATD therapy, radioactive iodine, and surgical interventions in managing pediatric GD. Additionally, novel therapies aimed at B-cells or the thyroid-stimulating hormone receptor, both implicated in the pathogenesis of GD, are under investigation. However, their definitive role in treating childhood GD has yet to be established. This review will cover the latest developments in the treatment of childhood GD, including information on emerging targeted therapies.

Keyword

Adolescent; Child; Graves disease; Hyperthyroidism; Therapeutics

Reference

References

1. Hanley P, Lord K, Bauer AJ. Thyroid disorders in children and adolescents: a review. JAMA Pediatr. 2016; 170(10):1008–1019. DOI: 10.1001/jamapediatrics.2016.0486. PMID: 27571216.

2. Quintanilla-Dieck L, Khalatbari HK, Dinauer CA, Rastatter JC, Chelius DC Jr, Katowitz WR, et al. Management of pediatric graves disease: a review. JAMA Otolaryngol Head Neck Surg. 2021; 147(12):1110–1118. DOI: 10.1001/jamaoto.2021.2715. PMID: 34647991.

3. Kakleas K, Kossyva L, Korona A, Kafassi N, Karanasios S, Karavanaki K. Predictors of associated and multiple autoimmunity in children and adolescents with type 1 diabetes mellitus. Ann Pediatr Endocrinol Metab. 2022; 27(3):192–200. DOI: 10.6065/apem.2142168.084. PMID: 34793669. PMCID: PMC9537678.

4. Simon M, Rigou A, Le Moal J, Zeghnoun A, Le Tertre A, De Crouy-Chanel P, et al. Epidemiology of childhood hyperthyroidism in France: a nationwide population-based study. J Clin Endocrinol Metab. 2018; 103(8):2980–2987. DOI: 10.1210/jc.2018-00273. PMID: 29846622.

5. Havgaard Kjaer R, Smedegård Andersen M, Hansen D. Increasing incidence of juvenile thyrotoxicosis in Denmark: a nationwide study, 1998-2012. Horm Res Paediatr. 2015; 84(2):102–107. DOI: 10.1159/000430985. PMID: 26111962.

6. Brent GA. Environmental exposures and autoimmune thyroid disease. Thyroid. 2010; 20(7):755–761. DOI: 10.1089/thy.2010.1636. PMID: 20578899. PMCID: PMC2935336.

7. Kalarani IB, Veerabathiran R. Impact of iodine intake on the pathogenesis of autoimmune thyroid disease in children and adults. Ann Pediatr Endocrinol Metab. 2022; 27(4):256–264. DOI: 10.6065/apem.2244186.093. PMID: 36567462. PMCID: PMC9816468.

8. Ross DS, Burch HB, Cooper DS, Carol Greenlee M, Laurberg P, Maia AL, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016; 26(10):1343–1421. DOI: 10.1089/thy.2016.0229. PMID: 27521067.

9. Mooij CF, Cheetham TD, Verburg FA, Eckstein A, Pearce SH, Léger J, et al. 2022 European thyroid association guideline for the management of pediatric Graves' disease. Eur Thyroid J. 2022; 11(1):e210073. DOI: 10.1530/ETJ-21-0073. PMID: 34981748. PMCID: PMC9142815.

10. Lane LC, Wood CL, Cheetham T. Graves' disease: moving forwards. Arch Dis Child. 2023; 108(4):276–281. DOI: 10.1136/archdischild-2022-323905. PMID: 35831126. PMCID: PMC10086272.

11. Sriussadaporn S, Pumchumpol W, Lertwattanarak R, Kunavisarut T. Efficacy of once daily versus divided daily administration of low daily dosage (15 mg/day) of methimazole in the induction of euthyroidism in Graves' hyperthyroidism: a randomized controlled study. Int J Endocrinol. 2017; 2017:2619695. DOI: 10.1155/2017/2619695. PMID: 29403532. PMCID: PMC5748309.

12. Rivkees SA. Approach to the patient: management and the long-term consequences of Graves' disease in children. J Clin Endocrinol Metab. 2022; 107(12):3408–3417. DOI: 10.1210/clinem/dgac573. PMID: 36184734.

13. Lee HG, Yang EM, Kim CJ. Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves' disease. Ann Pediatr Endocrinol Metab. 2021; 26(3):199–204. DOI: 10.6065/apem.2142046.023. PMID: 34610704. PMCID: PMC8505040.

14. Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, et al. Antithyroid drug treatment for Graves' disease in children: a long-term retrospective study at a single institution. Thyroid. 2014; 24(2):200–207. DOI: 10.1089/thy.2012.0612. PMID: 23926918.

15. van Lieshout JM, Mooij CF, Van Trotsenburg ASP, Zwaveling-Soonawala N. Methimazole-induced remission rates in pediatric Graves' disease: a systematic review. Eur J Endocrinol. 2021; 185(2):219–229. DOI: 10.1530/EJE-21-0077. PMID: 34061770.

16. Léger J, Carel JC. MANAGEMENT OF ENDOCRINE DISEASE: arguments for the prolonged use of antithyroid drugs in children with Graves' disease. Eur J Endocrinol. 2017; 177(2):R59–R67. DOI: 10.1530/EJE-16-0938. PMID: 28381452.

17. Wong TWC, Wong MYS. Remission in pediatric Graves' disease treated with antithyroid drug and the risk factors associated with relapse. Ann Pediatr Endocrinol Metab. 2022; 27(4):308–314. DOI: 10.6065/apem.2244038.019. PMID: 36567464. PMCID: PMC9816462.

18. Azizi F, Takyar M, Madreseh E, Amouzegar A. Long-term methimazole therapy in juvenile Graves' disease: a randomized trial. Pediatrics. 2019; 143(5):e20183034. DOI: 10.1542/peds.2018-3034. PMID: 31040197.

19. Azizi F. Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid. 2020; 30(10):1451–1457. DOI: 10.1089/thy.2019.0814. PMID: 32253999.

20. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2010; 2010(1):CD003420. DOI: 10.1002/14651858.CD003420.pub4. PMID: 20091544. PMCID: PMC6599817.

21. Lawrence N, Cheetham T, Elder C. How do paediatricians use and monitor antithyroid drugs in the UK? A clinician survey. Clin Endocrinol. 2019; 91(3):417–423. DOI: 10.1111/cen.14046. PMID: 31179554.

22. Wood CL, Cole M, Donaldson M, Dunger DB, Wood R, Morrison N, et al. Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis. Eur J Endocrinol. 2020; 183(6):637–645. DOI: 10.1530/EJE-20-0617. PMID: 33107439.

23. Vigone MC, Peroni E, Di Frenna M, Mora S, Barera G, Weber G. "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients. J Endocrinol Invest. 2020; 43(5):595–600. DOI: 10.1007/s40618-019-01144-0. PMID: 31713721.

24. Wood CL, Morrison N, Cole M, Donaldson M, Dunger DB, Wood R, et al. Initial response of young people with thyrotoxicosis to block and replace or dose titration thionamide. Eur Thyroid J. 2022; 11(1):e210043. DOI: 10.1530/ETJ-21-0043. PMID: 34981745. PMCID: PMC9142802.

25. Jawwad M, Ahmed SA, Zaidi SMM, Fatmi SAA, Ashraf MH, Naeem S, et al. Long-term outcome of treatments for Graves disease in the children and adolescent population. Endocrine. 2023; 81(2):223–230. DOI: 10.1007/s12020-023-03371-1. PMID: 37115377.

26. Lee SH, Lee SY, Chung HR, Kim JH, Kim JH, Lee YA, et al. Remission rate and remission predictors of Graves disease in children and adolescents. Korean J Pediatr. 2009; 52(9):1021–1028. DOI: 10.3345/kjp.2009.52.9.1021.

27. Song SM, Youn JS, Ko JM, Cheon CK, Choi JH, Yoo HW. The natural history and prognostic factors of Graves' disease in Korean children and adolescents. Korean J Pediatr. 2010; 53(4):585–591. DOI: 10.3345/kjp.2010.53.4.585.

28. Kim WK, Ahn BH, Han HS. The clinical course and prognostic factors to medical treatment of Graves' disease in children and adolescents. Ann Pediatr Endocrinol Metab. 2012; 17(1):33–38. DOI: 10.6065/apem.2012.17.1.33.

29. Song A, Kim SJ, Kim MS, Kim J, Kim I, Bae GY, et al. Long-term antithyroid drug treatment of Graves' disease in children and adolescents: a 20-year single-center experience. Front Endocrinol. 2021; 12:687834. DOI: 10.3389/fendo.2021.687834. PMID: 34194397. PMCID: PMC8236938.

30. Rho JG, Kum CD, Seo YJ, Shim YS, Lee HS, Hwang JS. Long-term outcomes of Graves' disease in children and adolescents receiving antithyroid drugs. Ann Pediatr Endocrinol Metab. 2021; 26(4):266–271. DOI: 10.6065/apem.2040286.143. PMID: 34015898. PMCID: PMC8749022.

31. Kim M. Commentary on "long-term outcomes of Graves' disease in children and adolescents receiving antithyroid drugs". Ann Pediatr Endocrinol Metab. 2021; 26(4):217. DOI: 10.6065/apem.2120143edi01. PMID: 34991298. PMCID: PMC8749019.

32. Kim JH. Commentary on "remission in pediatric Graves' disease treated with antithyroid drug and the risk factors associated with relapse". Ann Pediatr Endocrinol Metab. 2022; 27(4):245–246. DOI: 10.6065/apem.2222019edi04. PMID: 36567460. PMCID: PMC9816460.

33. Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, Salerno M, et al. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr. 2014; 164(5):1189–1194.E1. DOI: 10.1016/j.jpeds.2013.12.047. PMID: 24518168.

34. Léger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C. French Childhood Graves' Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. J Clin Endocrinol Metab. 2012; 97(1):110–119. DOI: 10.1210/jc.2011-1944. PMID: 22031519.

35. Trout AT, Khalatbari H, Shogbesan G, Mirza SK, Sharp SE, Alazraki A, et al. Radioiodine treatment of pediatric Graves disease: a multicenter review. Pediatr Radiol. 2023; 53(1):21–27. DOI: 10.1007/s00247-022-05415-6. PMID: 35750940.

36. Lutterman SL, Zwaveling-Soonawala N, Verberne HJ, Verburg FA, Van Trotsenburg ASP, Mooij CF. The efficacy and short- and long-term side effects of radioactive iodine treatment in pediatric Graves' disease: a systematic review. Eur Thyroid J. 2021; 10(5):353–363. DOI: 10.1159/000517174. PMID: 34540705. PMCID: PMC8406249.

37. Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab. 2004; 89(9):4229–4233. DOI: 10.1210/jc.2003-031223. PMID: 15356012.

38. Baumgarten HD, Bauer AJ, Isaza A, Mostoufi-Moab S, Kazahaya K, Adzick NS. Surgical management of pediatric thyroid disease: complication rates after thyroidectomy at the Children's hospital of Philadelphia high-volume pediatric thyroid center. J Pediatr Surg. 2019; 54(10):1969–1975. DOI: 10.1016/j.jpedsurg.2019.02.009. PMID: 30902456.

39. Choe Y, Lee YJ, Shin CH, Chung EJ, Lee YA. Risk factors of postoperative hypoparathyroidism after total thyroidectomy in pediatric patients with thyroid cancer. Ann Pediatr Endocrinol Metab. 2023; 28(1):26–33. DOI: 10.6065/apem.2244044.022. PMID: 35798302. PMCID: PMC10073022.

40. Weber T, Hummel R, Vorländer C, Zielke A, Hermann M, Krappitz A, et al. Thyroid surgery in children and adolescents: results from a multi-institutional German and Austrian database. Br J Surg. 2023; 110(12):1808–1814. DOI: 10.1093/bjs/znad255. PMID: 37758484.

41. Zaat AS, Derikx JPM, Zwaveling-Soonawala N, Van Trotsenburg ASP, Mooij CF. Thyroidectomy in pediatric patients with Graves' disease: a systematic review of postoperative morbidity. Eur Thyroid J. 2020; 10(1):39–51. DOI: 10.1159/000511345. PMID: 33777818. PMCID: PMC7983567.

42. Sjölin G, Holmberg M, Törring O, Byström K, Khamisi S, De Laval D, et al. The long-term outcome of treatment for Graves' hyperthyroidism. Thyroid. 2019; 29(11):1545–1557. DOI: 10.1089/thy.2019.0085. PMID: 31482765.

43. El Kawkgi OM, Ross DS, Stan MN. Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: a review of the literature. Clin Endocrinol. 2021; 95(1):3–12. DOI: 10.1111/cen.14374. PMID: 33283314.

44. Lane LC, Cheetham TD, Perros P, Pearce SHS. New therapeutic horizons for Graves' hyperthyroidism. Endocr Rev. 2020; 41(6):873–884. DOI: 10.1210/endrev/bnaa022. PMID: 32845332. PMCID: PMC7567404.

45. Smith TJ, Hegedus L. Graves' disease. N Engl J Med. 2016; 375(16):1552–1565. DOI: 10.1056/NEJMra1510030. PMID: 27797318.

46. Cheetham TD, Cole M, Abinun M, Allahabadia A, Barratt T, Davies JH, et al. Adjuvant rituximab: exploratory trial in young people with Graves disease. J Clin Endocrinol Metab. 2022; 107(3):743–754. DOI: 10.1210/clinem/dgab763. PMID: 34687316. PMCID: PMC8851941.

47. Kahaly GJ, Stan MN, Frommer L, Gergely P, Colin L, Amer A, et al. A novel anti-CD40 monoclonal antibody, iscalimab, for control of Graves hyperthyroidism: a proof-of-concept trial. J Clin Endocrinol Metab. 2020; 105(3):696–704. DOI: 10.1210/clinem/dgz013. PMID: 31512728.

48. Janes J, Kahaly G, Liang S, Tedeschi P. ODP509 proof-of-concept, multicenter, open-label phase 2a study of batoclimab in active and moderate-to-severe thyroid eye disease. J Endocr Soc. 2022; 6((Suppl 1)):A778–A779. DOI: 10.1210/jendso/bvac150.1609. PMCID: PMC9625233.

49. Furmaniak J, Sanders J, Sanders P, Li Y, Rees Smith B. TSH receptor specific monoclonal autoantibody K1-70™ targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy: results from a phase I clinical trial. Clin Endocrinol. 2022; 96(6):878–887. DOI: 10.1111/cen.14681. PMID: 35088429. PMCID: PMC9305464.

50. Pearce SHS, Dayan C, Wraith DC, Barrell K, Olive N, Jansson L, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study. Thyroid. 2019; 29(7):1003–1011. DOI: 10.1089/thy.2019.0036. PMID: 31194638. PMCID: PMC6648194.